Activating mutations in receptor tyrosine kinases (RTKs) have been detected in various types of malignant diseases such as lung cancer, hepatocellular carcinoma, and acute myeloid leukemia (AML)1. This evidence concerns the gene NTRK1 and acute myeloid leukemia.